


Design, synthesis and biological evaluation of VEGFR-2/HDAC dual inhibitors as multitargeted antitumor agents based on the Fruquintinib and Vorinostat


¹H-NMR of intermediate **3a**











¹H-NMR of intermediate 4














¹H-NMR of intermediate 8








HRMS (ESI) of intermediate 10a




Page 1 of 1


HRMS (ESI) of intermediate 10b




HRMS (ESI) of intermediate 10c




Page 1 of 1







HRMS (ESI) of intermediate 10f




HRMS (ESI) of intermediate 10g




HRMS (ESI) of intermediate 10h



HRMS (ESI) of intermediate 10j



HRMS (ESI) of intermediate 10k





HRMS (ESI) of intermediate 101

			谱图	旧报告			Agilent Trusted Answ
名称 进样体积. (ul) 数据文件	Sample34 5 LF-10F. d	样品架位置 样品盘位置	80meoh20water-10min- neg.m	仪器 IRM 状态 注释	Instrument 1 所有错失的离子	操作者	
		方法 (Acq)				采集时间(本地)	2023/5/18 16:33:20 (UTC+08:00)
x10 ⁴ -ESI 扫描 (rt: 2.022-2.138 min, 8	扫描数) Frag=120.0V LF-10F.d					
-			548.2410				
5.8-							
5.6-							
5.4-							
5.2-							
5-							
4.8-							
4.6- 4.4-							
4. 2							
4-							
3.8							
3.6							
3.4-							
3.2-							
3-							
2.8							
2.6							
2.4							
2.2-							
2-							
1.8							
1.6-							
1.4-							
1.2-							
1-							
0.8-							
0.6							
0.4							
0.2							
0-		18. 235 548. 236 548. 237 548. 238	549 220 549 24 549 241	549 242 549 242 5	49 244 549 245 549 246 549 2	17 549 249 549 240 549	25 549 251 549 252 549 252
540.	202 010, 200 010, 201 0	10, 200 010, 200 040, 201 040, 200		vs. 质荷比 (m/z)	10.211 010.210 010.210 010.2	1 010.210 010.210 010.2	O 010, 201 010, 202 010, 200


Page 1 of 1


Generated at 20:54 on 2023/6/7






¹H-NMR of compound 12








HPLC of compound 13




		结果表(不计算 - G:\liuhan\NX160-3 - 通道 1)								
	保留时间 [min]	峰面积 [mAU.s]	峰高 [mAU]	面积 [%]	峰高 [%]	W05 [min]	PDA峰纯度	化合物名称		
1	3.318	97.802	7.658	5.3	6.5	0.27	838			
2	3.397	6.143	3.421	0.3	2.9	0.03				
3	11.430	1739.623	107.067	94.4	90.6	0.26				
	合计	1843.569	118.145	100.0	100.0					










¹³C-NMR of compound **14**







¹³C-NMR of compound **15**







¹³C-NMR of compound 16







¹³C-NMR of compound **17**










¹³C-NMR of compound **18**







¹³C-NMR of compound **19**







¹³C-NMR of compound **20**







¹³C-NMR of compound **21**







¹³C-NMR of compound **22**







¹³C-NMR of compound **23**










¹³C-NMR of compound **24**







¹³C-NMR of compound **25**








¹³C-NMR of compound **26**















¹³C-NMR of compound **28**












¹³C-NMR of compound **31**







¹³C-NMR of compound **32**





¹H-NMR of compound 33




¹³C-NMR of compound **33**












¹³C-NMR of compound **36**





¹H-NMR of compound **38**



¹³C-NMR of compound **38**

